Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02957760

Acronym

PNPRO_HC

Enrollment

Registered

2016-11-08

Start date

2015-12-31

Completion date

2017-12-31

Last updated

2016-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Retinal Vein Occlusion, Non-Ischemic

Brief summary

The central retinal vein occlusion (CRVO) is a major cause of ocular morbidity, depending in particular on the occurrence and extent of retinal ischemia by capillary occlusion. There is no effective systemic treatment of this condition. An increase in the adhesion of erythrocytes to vascular endothelium was observed for patients with CRVO, correlated with overexpression of membrane phosphatidylserine

Detailed description

introduction : The central retinal vein occlusion (CRVO) is a major cause of ocular morbidity, depending in particular on the occurrence and extent of retinal ischemia by capillary occlusion. There is no effective systemic treatment of this condition. An increase in the adhesion of erythrocytes to vascular endothelium was observed for patients with CRVO, correlated with overexpression of membrane phosphatidylserine. Hypothesis : Hydroxycarbamide (HC) by reducing the erythrocyte adhesion to the endothelium may prevent or delay the onset of retinal capillary non-perfusion in patients with CRVO. Primary objective: To assess the efficacy at 3 months of treatment with HC on retinal capillary perfusion in patients with a recent CRVO. Secondary Objectives: To evaluate the safety of the treatment, the efficacy to 6 months on retinal perfusion of the treatment with HC (HC peak effect on the red cell adhesion in vitro), and the biological effects of HC, in particular on adhesion to endothelium and erythrocyte hemorheological parameters.

Interventions

DRUGHydroxycarbamid

20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients of both sexes of at least 45 years of age. * with social protection * Presenting CRVO for less than 1 month duration * With a decrease of visual acuity and with the best corrected visual acuity lower than 6/10 (73 ETDRS letters) * Signature of informed consent

Exclusion criteria

* predictable lack of compliance to the protocol * monophtalmic patient or any ocular history or condition that could interfere with the study course or results interpretation. * active systemic disease * sickle cell disease * myeloproliferative disease * myelosuppression * kidney or liver insufficiency * ongoing treatment with hydroxycarbamide or anticoagulant * Pregnancy, breast-feeding, no efficient contraception (for both sexes) * wish of paternity (for males of al least 45 years of age)

Design outcomes

Primary

Measure	Time frame	Description
retinal capillary non-perfusion	3 months	To assess the percentage of subjects in whom one of the following events will not be observed at W13 (any event being considered as one of the criteria of worsening of retinal capillary non-perfusion): * Occurence of at least one direct sign of retinal ischemia: Increase of more than 30% of peripheral retinal non-perfusion on large-field angiography or of the central avascular zone of the retina, * Occurence of at least one indirect sign of retinal ischemia: reperfusion of the aterial iris circle, rubeosis iridis, neovascular glaucoma or abolition of the afferent pupillary reflex.

Secondary

Measure	Time frame	Description
retinal capillary non-perfusion	2 weeks, 2 months and 6 months	Same criteria of retinal non perfusion as for primary end point
Hydroxycarbamide safety - visual acuity and retinal thickness. Biological in vitro effects on erythrocyte adhesion to vascular endothelium and various haemorheological parameters.	2 weks, 2 months, 3 months and 6 months	HC effect on visual acuity and retinal thickness. Biological in vitro effects on erythrocyte adhesion to vascular endothelium and various haemorheological parameters.

Countries

France

Contacts

Primary ContactLaurent Vinet

lvinet@15-20.com+33140021126

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026